Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ChemoCentryx Inc.

This article was originally published in Start Up

Executive Summary

Founded by chemokine pioneer and the discoverer of RANTES, Dr. Thomas Schall, ChemoCentryx is pursuing anti-infective and immunotherapy applications of chemokines and their receptors.

You may also be interested in...



Hope Springs Eternal in Biopharma IPO Pricing but Bad Haircuts Continue

While START-UP first noted an industry-wide tendency to overestimate the prices IPO investors were willing to pay in early 2005, IPOs have regularly fallen short of the anticipated price ever since, with few exceptions.

Biopharma VCs Move to the Middle in 2006

While the venture capital community spent roughly the same in biopharma investments in 2006 as they did in 2005, they put considerably more money into mid-stage companies (Series B and C investments), and slightly less into Series A and mezzanine rounds, than they had in 2005.

Biopharma IPOs Start Swing Back to Nasdaq

The trend of biopharma IPOs eschewing Nasdaq for European and other exchanges reverses modestly in 2006.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC090032

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel